Argenx Se ARGX
NASDAQ ARGX
$1,033.15 -20.31 (-1.93%)
At close: Sep 4, 2026 · 4:00 PM EDT

Argenx Se (ARGX) Income towards Parent Company (2016 - 2026)

Argenx Se's (ARGX) quarterly Income towards Parent Company came in at $472.0 million in Q2 2026, up 92.37% on a YoY basis from $245.4 million in Q2 2025, and up 28.96% quarter-over-quarter from $366.0 million in Q1 2026.

Analysis

Argenx Se (ARGX) Income towards Parent Company (2016 - 2026) Analysis & Trends

Argenx Se (ARGX) has reported Income towards Parent Company for 11 consecutive years, with $472.0 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Income towards Parent Company rose 92.37% year-over-year to $472.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.7 billion (up 34.01% YoY), and the FY2025 full-year result was $1.3 billion, up 55.1% from the prior year.
  • Income towards Parent Company rose to $472.0 million in Q2 2026 per ARGX's latest filing, from $366.0 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $774.2 million in Q4 2024 and bottomed at -$235.0 million in Q3 2022.
  • Historically, Income towards Parent Company has averaged $108.8 million across 5 years, with a median of $97500.0 in 2023.
  • The sharpest annual moves came in 2022 and 2024: Income towards Parent Company tumbled 1157.6% in 2022, then jumped 880.62% in 2024.
  • Over 5 years, Income towards Parent Company stood at -$38.6 million in 2022, then slumped by 156.84% to -$99.2 million in 2023, then surged by 880.62% to $774.2 million in 2024, then tumbled by 31.16% to $532.9 million in 2025, then fell by 11.44% to $472.0 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered $472.0 million, $366.0 million, and $532.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn
10 BioNTech SE 26.24 Bn 12.58 Bn 10.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 472.00 Mn
Mar 31, 2026 366.00 Mn
Dec 31, 2025 532.95 Mn
Sep 30, 2025 344.26 Mn
Jun 30, 2025 245.36 Mn
Mar 31, 2025 169.00 Mn
Dec 31, 2024 774.16 Mn
Sep 30, 2024 91.41 Mn
Jun 30, 2024 29.07 Mn
Mar 31, 2024 -61.60 Mn
Dec 31, 2023 -99.17 Mn
Sep 30, 2023 -72.64 Mn
Jun 30, 2023 -94.37 Mn
Mar 31, 2023 -28.87 Mn
Dec 31, 2022 -38.61 Mn
Sep 30, 2022 -235.04 Mn
Jun 30, 2022 -208.75 Mn
Mar 31, 2022 -227.19 Mn
Dec 31, 2021 -237.82 Mn
Sep 30, 2021 -233.61 Mn